ArticleClinical pharmacology and therapeutics2025
Model-Informed Selection of the Recommended Phase 2 Dosage for Anti-TIGIT Immunotherapy Leveraging co-Expressed PD-1 Inhibitor Target Engagement.
Irina Kareva et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.